Filter posts

Biotech Could Miss a Multi-Billion Dollar Opportunity in Rare Disease

Drug development is expensive.  Drug development is risky.  Drug development takes a long time. The …

Cohen, Boyer & Tibbetts?

Ask any biotech professional about Stanley Cohen and Herbert Boyer and they will tell you …

Sanofi’s Chris Viehbacher: Trust, Respect Key in Pharma-Biotech Partnerships

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the …